Health
Immunotherapy after surgery offers recurrence-free survival advantage for patients with high-risk melanoma – News-Medical.Net
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either…
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021.
Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients…
-
Noosa News21 hours agoQueensland government and nurses and midwives reach in-principle pay deal after months of negotiation
-
Noosa News10 hours agoPill checking to resume in Queensland months after government axed funding
-
Noosa News20 hours agoBrisbane nation’s third-youngest capital; Leaders condemn anti-immigration rally
-
General23 hours agoAs Iran-Australia relations plunge to a new low, Tehran faces another diplomatic setback